Humanigen, Inc., has dosed the first COVID-19 patient in its Phase III study for lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. Catalent provides clinical supply support to Humanigen and its partners from its Philadelphia facility.   “We are honored to have supported Humanigen on this important project and have ensured that all possible resources were allocated to allow these trials to begin as soon as possible,” said Ricci ...